A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia - Wikidata - awgldk - TriplyDB

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

http://www.wikidata.org/entity/Q28263629

about

MimoDB 2.0: a mimotope database and beyond Recent Advances Toward the Discovery of Drug-Like Peptides De novo The pleiotropic effects of erythropoietin in infection and inflammation New autoantibody detection technologies yield novel insights into autoimmune disease Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles In vitro methods for peptide display and their applications.A screen for peptide agonists of the G-CSF receptor Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.The approval process for biosimilar erythropoiesis-stimulating agents An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.Immunodeficiency secondary to anticytokine autoantibodies Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).Anemia associated with chronic heart failure: current concepts.Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.Erythropoietin receptor response circuits Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.Erythropoiesis-stimulating agents for anemic patients with cancer.Recent developments in doping testing for erythropoietin.Anemia in chronic heart failure: can we treat? What to treat?Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Analytical challenges in the detection of peptide hormones for anti-doping purposes.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Peginesatide for the treatment of renal disease-induced anemia.Erythropoiesis stimulating agents: approaches to modulate activity.Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.The ESA scenario gets complex: from biosimilar epoetins to activin traps.Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise Blocking peptides and molecular mimicry as treatment for kidney disease.Introduction of biosimilar insulins in Europe.

P2860

Q24618988-A1782024-E712-4D02-8971-CF5243C7B8AB Q26770535-1C8B9EE9-6C24-4DD2-9AA3-FF3D3CFBFA7F Q26864149-734D19AC-5FED-41C6-857B-AB423517A1EE Q27000173-7624DC18-45F5-46FF-9483-95F1224BA830 Q28732847-8A84C2AD-3644-4FCA-9C68-9FB120B7B82A Q33917861-DDB48401-E392-4195-9F0C-F7B0BCF40262 Q33933699-082C2216-D814-461D-9E3B-A2E3A0EE488D Q33944531-30B061B2-3A93-4A6C-B5E0-674041F99C8B Q34124734-084201DD-F113-49EE-93E0-BA1C6E6E51AA Q34398392-E9CC1C28-CCD6-457E-85D4-7FCDE428A354 Q35094485-851C8B80-BAE0-4AFA-892C-29237C4C3056 Q35119023-80AE35CC-C9A3-4543-A088-352DD4487944 Q35904444-B4145B10-8B26-4283-B730-86E8BF7C17DF Q35985899-DEC4B5EF-3F16-4B5E-B316-383846A5D0E8 Q36039649-3F1F3DAD-93A9-4A0B-A650-E2B75B9F1039 Q36431597-B94FE8EB-1D5F-49F2-B4A0-DC68E3AE44B1 Q36600453-B6462ECC-777E-4E1E-9587-8BF56C24138F Q36733554-C4730F7F-2812-4C8F-8E04-E94DD342A0F7 Q37157237-23D33406-28D7-4085-9699-8C78A13C0057 Q37257340-F543EB1E-C57B-47A4-8720-8CC1853C0E52 Q37359343-7E05D8CF-D8D5-4213-9147-06B3F19EE723 Q37696206-B4965B7A-CD05-4143-82DD-66322CD5D9FC Q37700912-55FD877D-AAEB-4410-BBE3-4DCF7BEE9A11 Q37702223-B2C8AB35-7D9F-4D6D-A0AF-866C0F7E7B97 Q37810966-BB5C408F-26DF-4B77-949C-EA935C0B525C Q37884431-4E549A3C-A813-4E28-B7C5-66BA52C1F6CF Q37943240-1A8798CD-E968-42FA-902A-4324246E00E9 Q37999380-5D175FAC-C0F3-4B19-B78C-3D60160D1F8C Q38029406-18D26A6E-4304-4A0D-A8EB-192420B376B2 Q38075798-F0B275EA-91A9-42A7-93EC-C24C97B768C6 Q38090725-40E80208-A763-4911-8565-6CAD5D289856 Q38121067-9FE8FE89-AC8C-4B09-BE2F-64421E156C1D Q38134288-7BBD62AC-98C4-40A8-8BDA-C838F6A8BB2B Q38205752-6BD62876-66E0-446A-BF65-C4180B39278C Q38595266-B1C9FCCC-E281-4BA5-ACC9-6C470F2CED5A Q38666170-CA895EFC-4A05-4C98-840F-BB218DF2A3FE Q38708467-4774937F-E545-42F4-819F-9E9E5368CBEA Q38934661-6F96F76D-4486-4A3B-BEF0-A4932F65BE89 Q38961136-4E8D1AFA-DF13-4899-9C26-FE8A3FD99C88 Q39368850-4C247A57-A023-411A-8539-BB0E732A853E

P2860

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

http://www.wikidata.org/entity/Q28263629

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@ast

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@en

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@nl

type

label

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@ast

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@en

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@nl

prefLabel

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@ast

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@en

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@nl

P1433

Q28263629-075CF8A5-1807-4F02-8869-BDDAAD36810C

P1476

Q28263629-C9A88C4B-C2C1-4B52-AA3B-FFF34FB16B7C

P2093

Q28263629-22A27553-EA17-4A9E-8F55-CA609BE3DA8E

Q28263629-348C6DE8-26ED-45EB-A0FD-7FE84560F2E6

Q28263629-44407985-99C5-4DB3-9BE3-0E16E8D9F2FF

Q28263629-654BB392-C96E-4064-AF25-E5EA7FE113A2

Q28263629-8DA55F36-A014-4973-9925-FA28F6D637AC

Q28263629-92C4C01F-A774-4E69-8DFD-FD73D56F3793

Q28263629-BDC63B12-D1FC-4FFD-8018-919A4DFABACA

P304

Q28263629-4090CB09-B1B8-4EF4-B8BF-236AC0717E80

P31

Q28263629-A106BA6A-C625-482C-A2EE-9CC090F82BA0

P356

Q28263629-85F1E66E-86DB-41CF-9BDD-19D619BA6CE7

P407

Q28263629-C2A5D7DA-23F3-4CBB-A00D-EEF563FB0E78

P433

Q28263629-B37B6DE6-7530-45E0-8B19-1A6C8415E84F

P478

Q28263629-915076B4-7CB0-43A4-8901-23FD5EA47434

P577

Q28263629-D80829B5-FA1C-4871-AAEF-76CD08BC912B

P698

Q28263629-AB43F2C2-B0ED-41BD-B256-9A0FAF8BB75E

P921

Q28263629-3F49D8F1-B906-49D4-80D1-49C5906E3AD8

P356

P1433

The New England Journal of Medicine

P1476

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

@en

P2093

Anne-Marie Duliege

http://www.w3.org/2001/XMLSchema#string

Iain C Macdougall

http://www.w3.org/2001/XMLSchema#string

Jerome Rossert

http://www.w3.org/2001/XMLSchema#string

Kai-Uwe Eckardt

http://www.w3.org/2001/XMLSchema#string

Marc Froissart

http://www.w3.org/2001/XMLSchema#string

Nicole Casadevall

http://www.w3.org/2001/XMLSchema#string

Richard B Stead

http://www.w3.org/2001/XMLSchema#string

P304

1848-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA074037

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19890127

http://www.w3.org/2001/XMLSchema#string

P921